Stockreport

U.S. FDA Accepts Supplemental Biologics License Application (sBLA) for ULTOMIRIS® (ravulizumab-cwvz) under Priority Review for the Treatment of Atypical Hemolytic Uremic Syndrome (aHUS)

Alexion Pharmaceuticals, Inc (ALXN)

More Company Research Source: Business Wire

Last alexion pharmaceuticals, inc earnings: 1/30 06:30 am Check Earnings Report

US:NASDAQ Investor Relations: ir.alexion.com/investor-relations

PDF - FDA sets target action date of October 19, 2019 - BOSTON--(BUSINESS WIRE)--Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) today announced that the U.S. Food and Drug A [Read more]

EVENT DAY Stock performance from the time of news release until the following 4pm ET market close	LAST PRICE AT NEWS EVENT {{SecondSection.LastPriceAtNewsEvent}}	SINCE EVENT Multi-day stock performance from the time of the news release
{{FirstSection.LastPrice}}	LAST PRICE	{{SecondSection.LastPrice}}
{{FirstSection.VWapStr_AMP}} {{FirstSection.VwapEventTime}}	VWAP	{{SecondSection.VWapStr_AMP}} {{SecondSection.VwapEventTime}}
{{FirstSection.MaxUp}} High: {{FirstSection.EodHigh}}	MAX UP	{{SecondSection.MaxUp}} High: {{SecondSection.EodHigh}}
{{FirstSection.MaxDown}} Low: {{FirstSection.EodLow}}	MAX DOWN	{{SecondSection.MaxDown}} Low: {{SecondSection.EodLow}}
{{FirstSection.TodaysRangeStr_AMP}} {{FirstSection.RangEvg}}	POST NEWS RANGE	{{SecondSection.TodaysRangeStr_AMP}} {{SecondSection.RangEvg}}
{{FirstSection.PriceChange}} {{FirstSection.PriceChangeTriangle_AMP}}	PRICE CHANGE	{{SecondSection.PriceChange}} {{SecondSection.PriceChangeTriangle_AMP}}
{{FirstSection.PriceChangePercent}}	PRICE CHANGE PERCENTAGE	{{SecondSection.PriceChangePercent}}
{{FirstSection.Spx500}}	S&P 500 (SPX)	{{SecondSection.Spx500}}
{{FirstSection.VolumeImpactStr_AMP}}	VOLUME RATIO	{{SecondSection.VolumeImpactStr_AMP}}
{{FirstSection.Volume}}	VOLUME (SHARES)	{{SecondSection.Volume}}
{{FirstSection.TicksString}}	TICKS	{{SecondSection.TicksString}}
{{FirstSection.AvgTransactionSizeStr_AMP}}	AVG SHARES PER TRADE	{{SecondSection.AvgTransactionSizeStr_AMP}}

In short, News Quantified specializes in matching financial news with market data. We've analyzed 10s of millions of news events and know exactly which ones have an outsized impact on stock prices. So every single time a news item is released we know exactly what the average effect will be on a particular stock.

U.S. FDA Accepts Supplemental Biologics License Application (sBLA) for ULTOMIRIS® (ravulizumab-cwvz) under Priority Review for the Treatment of Atypical Hemolytic Uremic Syndrome (aHUS)

{{GreenBoxData.Blurb}}

Opt in for alerts from News Quantifed